I-Mab Biopharma GAAP EPS of -$0.07 misses by $0.02

* I-Mab Biopharma press release [https://seekingalpha.com/pr/20206192-i-mab-reports-second-quarter-2025-financial-results-and-provides-business-update] (NASDAQ:IMAB [https://seekingalpha.com/symbol/IMAB]): Q2 GAAP EPS of -$0.07 misses by $0.02.
* As of June 30, 2025, the Company had cash and cash equivalents, and short-term investments of $165.6 million. The Company expects that its existing cash and cash equivalents, and short-term investments, together with the net proceeds from the August 2025 underwritten offering, will be sufficient to fund its operating expenses and capital expenditure requirements through the fourth quarter of 2028, including through a randomized Phase 2 trial of givastomig.

MORE ON I-MAB BIOPHARMA

* I-Mab prices $65M ADS offering [https://seekingalpha.com/news/4476510-i-mab-prices-65m-ads-offering]
* I-Mab to buy Bridge Health to strengthen cancer drug development [https://seekingalpha.com/news/4468419-i-mab-to-buy-bridge-health-biotech]
* Seeking Alpha’s Quant Rating on I-Mab Biopharma [https://seekingalpha.com/symbol/IMAB/ratings/quant-ratings]
* Historical earnings data for I-Mab Biopharma [https://seekingalpha.com/symbol/IMAB/earnings]
* Financial information for I-Mab Biopharma [https://seekingalpha.com/symbol/IMAB/income-statement]